Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion type Assertion NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_head.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion wasGeneratedBy ECO_0000203 NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion wasDerivedFrom befree-20140225 NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion SIO_000772 22271575 NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion evidence source_evidence_literature NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.
- NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.